Brief: GRI Bio’s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect Of GRI-0621
08/05/2025 16:09
May 8 (Reuters) - GRI Bio Inc GRI.O: GRI BIO’S INTERIM BIOMARKER DATA DEMONSTRATE POSITIVE TREND TOWARDS ANTI-FIBROTIC EFFECT OF GRI-0621 IN FIRST TWELVE PATIENTS OF ONGOING PHASE 2A STUDY IN IDIOPATHIC PULMONARY FIBROSIS (“IPF”) GRI BIO INC - INTERIM DATA EXPECTED Q2 2025, TOPLINE DATA Q3 2025 Source text: ID:nGNX8CcK52 Further company coverage: GRI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on GRI Bio
See all newsGRI Bio Inc reports results for the quarter ended June 30 - Earnings Summary
GRI Bio Inc expected to post a loss of $1.19 a share - Earnings Preview
Brief: Gri Bio Secures FDA Orphan Drug Designation For Gri-0621 (Tazarotene) In Idiopathic Pulmonary Fibrosis
GRI Bio Q1 net loss narrows on lower R&D expenses
GRI Bio raises $14.5 mln to fund operations into Q1 2027